From Despair to Remission: Successful Treatment of Eosinophilic Esophagitis with Dupiluamb: Two Case Reports from Qatar

World Allergy Organization Journal 2026 Open access

Read full text
Authors: Mohamed Elhadi, Sami Aqil, Asaad Omer Imameldin, Abulgasim Ennkaa, Maryam Ali Al‐Nesf, Hassan Mobayed, Tayseer Ibrahim
DOI: 10.1016/j.waojou.2026.101311
Cited by: 0
References: 3

Abstract

Eosinophilic esophagitis (EoE) is a chronic, immune-mediated disease that significantly impacts quality of life (QoL). Long-standing or untreated inflammation can lead to fibrostenotic disease, thereby increasing the disease burden. EoE treatment aims to alleviate symptoms, normalise endoscopic changes, and ultimately improve QoL. Dupilumab, an anti-IL4 monoclonal antibody, was approved for EoE treatment. Here, we report two cases of EoE that have been successfully treated with Dupilumab at the Adult Allergy and Immunology clinic at HMC Qatar.

Fields of Study & Subjects

Eosinophilic Esophagitis Asthma and respiratory diseases Food Allergy and Anaphylaxis Research

Publication details

Journal / source
World Allergy Organization Journal
Volume
19
Issue
2
Pages
101311–101311
Publication date
1 February 2026
Language
EN